Vijaya Diagnostic Centre Limited Asset Resilience Ratio
Vijaya Diagnostic Centre Limited asset resilience ratio. Vijaya Diagnostic Centre Limited (VIJAYA) has an Asset Resilience Ratio of 15.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VIJAYA days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vijaya Diagnostic Centre Limited (2019–2026)
Asset resilience ratio of Vijaya Diagnostic Centre Limited from 2019 to 2026. This chart shows how Vijaya Diagnostic Centre Limited's Asset Resilience Ratio has changed over time. Read total liabilities of Vijaya Diagnostic Centre Limited for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vijaya Diagnostic Centre Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Vijaya Diagnostic Centre Limited asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.28 Billion | 15.15% |
| Total Liquid Assets | Rs2.28 Billion | 15.15% |
Asset Resilience Insights
- Good Liquidity Position: Vijaya Diagnostic Centre Limited maintains a healthy 15.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Vijaya Diagnostic Centre Limited Industry Peers by Asset Resilience Ratio
Compare Vijaya Diagnostic Centre Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Vijaya Diagnostic Centre Limited Asset Resilience Ratio by Year (2019–2026)
Vijaya Diagnostic Centre Limited asset resilience ratio by year from 2019 to 2026. The table below shows the annual Asset Resilience Ratio data for Vijaya Diagnostic Centre Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 15.15% | Rs2.28 Billion ≈ $24.70 Million |
Rs15.07 Billion ≈ $162.98 Million |
+0.66pp |
| 2025-03-31 | 14.49% | Rs1.85 Billion ≈ $19.96 Million |
Rs12.74 Billion ≈ $137.74 Million |
+3.39pp |
| 2024-03-31 | 11.10% | Rs1.09 Billion ≈ $11.80 Million |
Rs9.83 Billion ≈ $106.28 Million |
-15.99pp |
| 2023-03-31 | 27.10% | Rs2.31 Billion ≈ $25.01 Million |
Rs8.53 Billion ≈ $92.29 Million |
-2.91pp |
| 2022-03-31 | 30.01% | Rs2.14 Billion ≈ $23.15 Million |
Rs7.13 Billion ≈ $77.16 Million |
-9.35pp |
| 2021-03-31 | 39.36% | Rs2.13 Billion ≈ $23.02 Million |
Rs5.41 Billion ≈ $58.50 Million |
+15.49pp |
| 2020-03-31 | 23.86% | Rs1.15 Billion ≈ $12.45 Million |
Rs4.82 Billion ≈ $52.15 Million |
-3.16pp |
| 2019-03-31 | 27.03% | Rs1.10 Billion ≈ $11.88 Million |
Rs4.06 Billion ≈ $43.95 Million |
-- |
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T ser… Read more